Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
WADA Prohibition While GLP1 and cagrilintide individually have not been explicitly listed by WADA, several considerations apply: GLP-1 agonist precedent Other GLP-1 agonists are monitored for potential misuse in athletics Weight-class sports concern Rapid weight reduction capabilities raise concerns for sports with weight classifications Performance-enhancing potential Metabolic effects could theoretically affect athletic performance Monitoring program possible May be added to WADA monitoring program as use increases Athletes should consult with their sports governing bodies and anti-doping authorities before considering any GLP-1 or amylin analogue use
PubMed American Diabetes Association Professional Practice Committee
doi: 10.1186/s12986-019-0410-3 55 XuYHuangXHuangfuBHuYXuJGaoRet al
No dose adjustment is required for elderly patients based on age alone
Working well
